Scientific insights

Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.

Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.

This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.

At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.

Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular

ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for

Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25

The FLF’s Precision Medicine Programme Research Goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in

Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has

Interesting summary of the impact and effectiveness of antibody responses to SARS- CoV-2 vaccines in patients with hematologic malignancies. A project from Michael J. Garil

For many people living with Follicular Lymphoma, periodic blood tests become a regular feature. There are several reasons you might need blood tests when affected

At the American Society for Hematology (ASH) Annual Meeting in December 2021, the most up-to-date research was shared on Follicular Lymphoma (FL), as well as

Any potential treatments for Follicular Lymphoma (and other forms of Non-Hodgkin lymphoma) must undergo extensive testing. They must be fully researched to confirm that they

The FLF places the patient at the heart of our organisation. This survey collated the unmet needs and prioritised our research goals.